Immunosuppressant therapy successfully improved regorafenib-induced severe hepatic injury in a patient with metastatic gastrointestinal stromal tumor: A case report

Kuwayama,Miyuki; Uchino,Keita; Takayoshi,Kotoe; Komoda,Masato; Kohjima,Motoyuki; Nakamuta,Makoto; Momosaki,Seiya; Kusaba,Hitoshi; Akashi,Koichi; Baba,Eishi

doi:10.3892/ol.2015.3853

January-2016 Volume 11 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-2016 Volume 11 Issue 1

Full Size Image

Case Report Open Access

Immunosuppressant therapy successfully improved regorafenib-induced severe hepatic injury in a patient with metastatic gastrointestinal stromal tumor: A case report

Authors:
- Miyuki Kuwayama
- Keita Uchino
- Kotoe Takayoshi
- Masato Komoda
- Motoyuki Kohjima
- Makoto Nakamuta
- Seiya Momosaki
- Hitoshi Kusaba
- Koichi Akashi
- Eishi Baba
View Affiliations / Copyright

Affiliations: Department of Medical Oncology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka 810‑0065, Japan, Department of Gastroenterology, National Hospital Organization Kyushu Medical Center, Fukuoka 810‑0065, Japan, Department of Pathology, National Hospital Organization Kyushu Medical Center, Fukuoka 810‑0065, Japan, Department of Hematology and Oncology, Kyushu University Hospital, Fukuoka 812‑8582, Japan, Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, Fukuoka 812‑8582, Japan

Copyright: © Kuwayama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 85-88
|
Published online on: November 2, 2015

https://doi.org/10.3892/ol.2015.3853
Expand metrics +

Abstract

A 75-year-old man diagnosed with ileal gastrointestinal tumor with peritoneal dissemination was subjected to salvage treatment with regorafenib at 120 mg/day. Following the initiation of the treatment, liver dysfunction appeared on day 28, and continued to worsen despite termination of the treatment. Since no increase in the levels of serum immunoglobulins of the patient was observed, and negative results were obtained for the analysis of viral markers and autoantibodies, a diagnosis of regorafenib‑induced hepatitis was suggested. In consequence, the patient received steroid pulse therapy and continuous administration of prednisolone, without sufficient improvement. Liver biopsy revealed interface hepatitis with prominent plasma cell infiltration, suggesting regorafenib‑induced autoimmune hepatitis. The patient was then administered azathioprine and prednisolone, which improved the hepatic injury. The present case represents the first report of successful treatment of regorafenib‑induced severe hepatic injury by the use of an immunosuppressant.

View Figures

View References

1	Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:577–580. 1998. View Article : Google Scholar : PubMed/NCBI
2	Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, et al: NCCN Task Force report: Update on the management of patients with gastrointestinal stromal tumors. Natl Compr Canc Netw 8. Suppl. 2:S1–S41. 2010.
3	Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, et al: GRID study investigators: Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381:295–302. 2013. View Article : Google Scholar : PubMed/NCBI
4	Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et al: CORRECT Study Group: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312. 2013. View Article : Google Scholar : PubMed/NCBI
5	Yamada Y, Yoshino T, Komatsu Y, Yamazaki K, Tsuji A, Ura T, Grothey A, Van Cutsem E, Wagner A and Ohtsu A: Safety and efficacy of regorafenib in Japanese patients with metastatic colorectal cancer: A subgroup analysis of the phase III CORRECT trial. Ann Oncol. 24(Suppl 9): ix31–ix65. 2013. View Article : Google Scholar
6	Leise MD, Poterucha JJ and Talwalkar JA: Drug-induced liver injury. Mayo Clin Proc. 89:95–106. 2014. View Article : Google Scholar : PubMed/NCBI
7	Czaja AJ: Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 56:958–976. 2011. View Article : Google Scholar : PubMed/NCBI
8	Björnsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, Neuhauser M and Lindor K: Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis. Hepatology. 51:2040–2048. 2010. View Article : Google Scholar : PubMed/NCBI
9	Krawitt EL: Autoimmune hepatitis. N Engl J Med. 354:54–66. 2006. View Article : Google Scholar : PubMed/NCBI
10	Lewis JH and Zimmerman HJ: Liver diseases. Auto-immune Liver Diseases. Krawitt EL, Wiesner RH and Nishioka K: (2nd). (Amsterdam, Netherlands). Elsevier. 627–649. 1998.
11	Hirano G, Makiyama A, Makiyama C, Esaki T, Oda H, Uchino K, Komoda M, Tanaka R, Matsushita Y, Mitsugi K, et al: Reduced-dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan. Anticancer Res. 35:371–377. 2015.PubMed/NCBI
12	Russmann S, Jetter A and Kullak-Ublick GA: Pharmacogenetics of drug-induced liver injury. Hepatology. 52:748–761. 2010. View Article : Google Scholar : PubMed/NCBI
13	Aliberti S, Grignani G, Allione P, Fizzotti M, Galatola G, Pisacane A and Aglietta M: An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient. Am J Clin Oncol. 32:640–641. 2009. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Immunosuppressant therapy successfully improved regorafenib-induced severe hepatic injury in a patient with metastatic gastrointestinal stromal tumor: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles